| Revista: | The brazilian journal of infectious diseases |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000290702 |
| ISSN: | 1413-8670 |
| Autores: | Jones, Ronald N1 Ballow, Charles H Biedenbach, Douglas J Rossi, Flavia |
| Instituciones: | 1The Jones Group/JMI Laboratories, North Liberty, Iowa. Estados Unidos de América |
| Año: | 2002 |
| Periodo: | Jun |
| Volumen: | 6 |
| Número: | 3 |
| Paginación: | 100-109 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Caso clínico, analítico |
| Resumen en inglés | ABSTRACT Linezolid was the first clinically applied member of the new antimicrobial class called the "oxazolidinones". These agents have a powerful spectrum of activity focussed against Gram-positive organisms including strains with documented resistances to other antimicrobial classes. We conducted a multicenter surveillance (Zyvox Antimicrobial Potency Study; ZAPS) trial of qualifying Gram-positive isolates from 24 medical centers in eight countries in Latin America. The activity and spectrum of linezolid was compared to numerous agents including glycopeptides, quinupristin/dalfopristin, b-lactams and fluoroquinolones when testing 2,640 strains by the standardized disk diffusion method or Etest (AB BIODISK, Solna, Sweden). The linezolid spectrum was complete against staphylococci (median zone diameter, 29 - 32 mm), as was the spectrum of vancomycin and quinupristin/dalfopristin. Among the enterococci, no linezolid resistance was detected, and the susceptibility rate was 93.1 - 96.4%. Only the vancomycin-susceptible Enterococcus faecium strains remained susceptible (92.8%) to quinupristin/dalfopristin. Marked differences in the glycopeptide resistance patterns (van A versus van B) were noted for the 22 isolates of VRE, thus requiring local susceptibility testing to direct therapy. Streptococcus pneumoniae and other species were very susceptible (100.0%) to linezolid, MIC90 at 0.75 mg/ml. Penicillin non-susceptible rate was 27.7% and erythromycin resistance was at 17.4%. Other streptococci were also completely susceptible to linezolid (MIC90, 1 mg/ml). These results provide the initial benchmark of potency and spectrum for linezolid in Latin American medical centers. Future comparisons should recognize that the oxazolidinones possess essentially a complete spectrum coverage of the monitored staphylococci, enterococci and streptococcal isolates in 2000-2001. This positions linezolid as the widest spectrum empiric choice against multi-resistant Gram-positive c |
| Disciplinas: | Medicina |
| Palabras clave: | Farmacología, Microbiología, Linezolid, Oxazolidinonas, Vigilancia, Streptococcus pneumoniae, Cocos Gram positivos |
| Keyword: | Medicine, Microbiology, Pharmacology, Linezolid, Oxazolidinones, Surveillance, Streptococcus pneumoniae, Gram positive cocci |
| Texto completo: | Texto completo (Ver HTML) |
